Global infectious disease drug development partnership aims to ‘stimulate pharma’

By Maggie Lynch contact

- Last updated on GMT

Global infectious disease drug development partnership aims to ‘stimulate pharma’

Related tags: Site selection, Pediatrics, Drug development, global market

Penta and Cromsource partner in an aim to improve pediatric drug development for infectious disease therapies worldwide.

The international contract research organization (CRO) Cromsource will work with the recently established Penta ID Innovation through this agreement. Penta ID Innovation is a site management organization developed from the Penta Global Pediatric Research Network.

Per the collaboration, Penta and Cromsource will work to establish and manage worldwide drug development programs for infectious diseases affecting pediatric populations.

Penta will bring its experience in pediatric infectious diseases to the table alongside Cromsource’s capabilities in managing global drug development programs for pediatric patients.

A spokesperson for Comsource and Penta told us that the partnership will target most pediatric infectious diseases and will “hopefully it will stimulate pharma to be more active in the field.”

According to the two companies, pediatric drug development poses several challenges that have to be taken into consideration. This includes patient enrollment and site selection, challenges which the companies aim to take on by involving many specialized sites in multiple countries.

 

Related news

Show more

Related products

show more

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars